735 related articles for article (PubMed ID: 22995029)
1. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
3. Systemic bevacizumab (Avastin) for exudative retinal detachment secondary to choroidal melanoma.
Newman H; Finger PT; Chin KJ; Pavlick AC
Eur J Ophthalmol; 2011; 21(6):796-801. PubMed ID: 21445839
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
5. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration.
Jonas JB; Libondi T; Golubkina L; Spandau UH; Schlichtenbrede F; Rensch F
Acta Ophthalmol; 2010 Sep; 88(6):630-4. PubMed ID: 19432871
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema.
Sheth S; Rush R; Natarajan S; Gillies M
Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections.
Alshareef RA; Garg SJ; Hsu J; Vander J; Park C; Spirn MJ
J Ocul Pharmacol Ther; 2014 Aug; 30(6):512-6. PubMed ID: 24828198
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
Tao Y; Jonas JB
J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion.
Wu WC; Cheng KC; Wu HJ
Eye (Lond); 2009 Dec; 23(12):2215-22. PubMed ID: 19218991
[TBL] [Abstract][Full Text] [Related]
11. Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema.
Liu Q; Hu Y; Yu H; Yuan L; Hu J; Atik A; Guan M; Li D; Li X; Tang S
Retina; 2015 Feb; 35(2):272-9. PubMed ID: 25105313
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.
Shah SU; Shields CL; Bianciotto CG; Iturralde J; Al-Dahmash SA; Say EAT; Badal J; Mashayekhi A; Shields JA
Ophthalmology; 2014 Jan; 121(1):269-275. PubMed ID: 24139123
[TBL] [Abstract][Full Text] [Related]
13. Regression of serous macular detachment due to peripheral exudative hemorrhagic chorioretinopathy following intravitreal bevacizumab.
Barkmeier AJ; Kadikoy H; Holz ER; Carvounis PE
Eur J Ophthalmol; 2011; 21(4):506-8. PubMed ID: 21240857
[TBL] [Abstract][Full Text] [Related]
14. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.
Mashayekhi A; Rojanaporn D; Al-Dahmash S; Shields CL; Shields JA
Eur J Ophthalmol; 2014; 24(2):228-34. PubMed ID: 23934823
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F; Hamasaki T; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):591-596.e1. PubMed ID: 19589497
[TBL] [Abstract][Full Text] [Related]
16. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.
Higashiyama T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ohji M
Acta Ophthalmol; 2013 Jun; 91(4):318-24. PubMed ID: 22132711
[TBL] [Abstract][Full Text] [Related]
18. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema.
Soheilian M; Garfami KH; Ramezani A; Yaseri M; Peyman GA
Retina; 2012 Feb; 32(2):314-21. PubMed ID: 22234244
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
Veritti D; Sarao V; Lanzetta P
J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
[TBL] [Abstract][Full Text] [Related]
20. Short-term complications of intravitreal injections of triamcinolone and bevacizumab.
Jonas JB; Spandau UH; Schlichtenbrede F
Eye (Lond); 2008 Apr; 22(4):590-1. PubMed ID: 18292795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
